{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/dhr-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/dhr-stock-analysis/data.json",
 "title": "Danaher (DHR) Stock Forecast & Price Target (2026)",
 "description": "Danaher Corp. (DHR) stock: Healthcare, Diagnostics & Research. $147.2B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Danaher Corp. (DHR)",
 "published": "2026-07-19T09:37:05+00:00",
 "modified": "2026-09-16T04:45:53.806+00:00",
 "generated": "2026-09-16T12:54:22.250Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "DHR",
  "name": "Danaher Corp.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Diagnostics & Research",
  "country": "United States",
  "website": "https://www.danaher.com"
 },
 "quote": {
  "price": 209.36,
  "previousClose": 203.25,
  "change": 6.11,
  "changePercent": 3.01,
  "open": 203.080002,
  "high": 209.55,
  "low": 202.62,
  "volume": 3504900,
  "averageVolume": 3105470,
  "marketCap": 147177160265,
  "fiftyTwoWeekHigh": 242.8,
  "fiftyTwoWeekLow": 160.92999,
  "marketOpen": false,
  "asOf": "2026-09-16T04:45:53.000Z"
 },
 "statistics": {
  "pe": 36.294643,
  "eps": 5.6,
  "dividendYield": 0.0076430688257846284,
  "beta": 0.808,
  "priceToSales": 5.6909194,
  "priceToBook": 2.7170281,
  "revenueTtm": 25106999296,
  "grossMargin": 0.5763766959297686,
  "returnOnEquity": 0.07605
 },
 "technicals": {
  "rsi": 40.47,
  "macd": 0.32,
  "sma50": 202.8,
  "sma200": 202.17,
  "rsiSignal": "Neutral",
  "trend": "Neutral",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 59,
  "consensus": "Hold",
  "fairValue": 209.36,
  "analystTarget": 230,
  "analystCount": 26,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-16T04:45:53.000Z",
  "priceAtAnalysis": 209.36,
  "volatility": {
   "daily": 1.84,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 207.27,
  "aggressiveEntry": 209.36,
  "stopLoss": 196.63,
  "stopLossPercent": 5.13,
  "targets": [
   213.48,
   217.63,
   223.85
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 163.98,
    "base": 229.33,
    "upside90th": 320.71
   },
   {
    "year": 2028,
    "downside10th": 156.32,
    "base": 251.19,
    "upside90th": 403.64
   },
   {
    "year": 2029,
    "downside10th": 153.92,
    "base": 275.15,
    "upside90th": 491.87
   },
   {
    "year": 2030,
    "downside10th": 154.1,
    "base": 301.39,
    "upside90th": 589.44
   },
   {
    "year": 2031,
    "downside10th": 155.95,
    "base": 330.13,
    "upside90th": 698.85
   },
   {
    "year": 2032,
    "downside10th": 159.02,
    "base": 361.61,
    "upside90th": 822.29
   },
   {
    "year": 2033,
    "downside10th": 163.09,
    "base": 396.1,
    "upside90th": 961.99
   },
   {
    "year": 2034,
    "downside10th": 168.03,
    "base": 433.87,
    "upside90th": 1120.31
   },
   {
    "year": 2035,
    "downside10th": 173.76,
    "base": 475.25,
    "upside90th": 1299.83
   },
   {
    "year": 2036,
    "downside10th": 180.25,
    "base": 520.57,
    "upside90th": 1503.42
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "DHR Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$203.08",
    "Day Range": "$202.62 to $209.55",
    "Prev Close": "$203.25",
    "Volume": "3.50M",
    "52-Week Range": "$160.93 to $242.80",
    "Market Cap": "$147.18B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (14% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "DHR Financial Performance",
   "text": [
    "Analysis: In the last 3 quarters, DHR beat estimates 2 times. However, the stock fell 1 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "DHR Analysis",
   "text": [
    "Danaher Corp. (DHR) is currently trading above its 50-day SMA of $202.80 and its 200-day SMA of $202.17, indicating a generally positive trend. The price is also above its 20-day EMA of $206.80. The Relative Strength Index (RSI) is at 40.47, which falls into the 'Neutral' momentum category, suggesting neither overbought nor oversold conditions. The MACD is slightly positive at 0.317, indicating some upward momentum. Volume on the latest trading day was 3,504,900, which is approximately 12.9% above the average daily volume of 3,105,470, suggesting increased investor interest. Key support levels are indicated by the moving averages, while the current price action suggests a neutral to slightly bullish short-term outlook. However, the lack of strong bullish or bearish signals from momentum indicators like the RSI suggests a period of consolidation or indecision.",
    "Insiders have sold over $507.5 million worth of Danaher Corp. (DHR) stock across 71 transactions, indicating significant divestiture pressure that could negatively impact stock performance.",
    "Danaher Corp. (DHR) has shown inconsistent earnings beats and misses in recent quarters, creating uncertainty around future earnings predictability and potentially limiting upside momentum.",
    "Danaher Corp.'s (DHR) revenue growth of 5.5% lags behind the healthcare sector median of 8.1%, suggesting potential challenges in market expansion or competitive positioning.",
    "A significant majority of Wall Street analysts maintain a 'Buy' rating on Danaher Corp. (DHR), with a median price target of $230, suggesting confidence in the company's future prospects.",
    "Danaher Corp. (DHR) is expected to maintain a stable outlook over the next 6-12 months, with its fair value assessment currently aligning with its trading price of $209.36. The median analyst target price of $230 suggests a potential upside of approximately 9.9%, reflecting Wall Street's confidence in the company's underlying business and its position within the healthcare sector. The company's strong profit margins and efficient operations provide a solid foundation for continued performance. However, the significant insider selling activity presents a considerable headwind and introduces an element of uncertainty. Should this selling pressure continue or intensify, it could weigh on the stock price, potentially negating the upside suggested by analyst targets. Conversely, any positive developments in revenue growth acceleration or successful integration of new technologies could serve as upside catalysts, potentially driving the stock towards the higher end of analyst price targets."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transaction activity closely, as the recent heavy selling pressure from insiders warrants caution despite positive analyst ratings.",
     "Given the neutral RSI reading, consider waiting for a clearer technical signal or a more attractive entry point before initiating a new position.",
     "The company's revenue growth is currently below sector averages; focus on its ability to innovate and expand market share to drive future top-line performance."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Activity",
     "text": "Insiders have sold over $507.5 million worth of Danaher Corp. (DHR) stock across 71 transactions, indicating significant divestiture pressure that could negatively impact stock performance.",
     "source": "Insider Transactions"
    },
    {
     "type": "Neutral",
     "title": "Mixed Earnings Performance",
     "text": "Danaher Corp. (DHR) has shown inconsistent earnings beats and misses in recent quarters, creating uncertainty around future earnings predictability and potentially limiting upside momentum.",
     "source": "Earnings Reports"
    },
    {
     "type": "Neutral",
     "title": "Below Sector Average Revenue Growth",
     "text": "Danaher Corp.'s (DHR) revenue growth of 5.5% lags behind the healthcare sector median of 8.1%, suggesting potential challenges in market expansion or competitive positioning.",
     "source": "Company Filings"
    },
    {
     "type": "Bullish",
     "title": "Positive Wall Street Analyst Sentiment",
     "text": "A significant majority of Wall Street analysts maintain a 'Buy' rating on Danaher Corp. (DHR), with a median price target of $230, suggesting confidence in the company's future prospects.",
     "source": "Analyst Ratings"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Danaher Corp. (DHR) presents a mixed fundamental picture when compared to its Healthcare sector peers. Its Price-to-Sales (P/S) ratio stands at 5.69, which is higher than the sector median of 3.7, suggesting the stock may be trading at a premium on a revenue basis. The company's Return on Equity (ROE) is 7.61%, exceeding the sector median of 6.9%, indicating efficient use of shareholder equity. Profitability metrics are strong, with a net profit margin of 15.95% and an operating margin of 19.78%, both of which are strong. However, its revenue growth of 5.5% lags behind the sector median of 8.1%. The debt-to-equity ratio of 0.53 is in line with the sector average, suggesting a balanced capital structure. While the company demonstrates strong profitability and efficiency, its growth rate is somewhat subdued compared to industry averages, and its valuation appears stretched on a P/S basis.",
    "Danaher Corp. (DHR) has shown mixed earnings performance in its recent reported quarters. For the quarter ending June 2026, the company reported an EPS of $1.17, beating the estimate of $1.10 by 6.36%, though the stock saw a slight decline of -0.58%. Prior to that, the quarter ending March 2026 saw an EPS of $2.72, surpassing estimates by 6.67% and resulting in a positive price change of 0.42%. However, an earlier quarter to June 2026 reported a negative EPS surprise of -14.29% (-$0.16 actual vs -$0.14 estimate), leading to a price increase of 1.54%. This pattern suggests inconsistent earnings beats and misses, making future earnings a point of uncertainty.",
    "The most significant risk for Danaher Corp. (DHR) is the heavy insider selling, with over $507 million in sales across 71 transactions, signaling potential negative sentiment from management. Additionally, the company's revenue growth of 5.5% is below the sector median, indicating potential challenges in expanding its top line. The stock's Price-to-Sales ratio of 5.69 is also higher than the sector average, suggesting a potentially overvalued position relative to its revenue generation."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "147.18B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "36.29"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "5.60"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.69%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "242.80"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "160.93"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Neutral SMA Cross Neutral Price vs SMA Bullish MACD Bullish Price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Neutral",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "40.47"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "0.32"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "202.80"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "202.17"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.40",
    "Correlation with Nasdaq 100 (QQQ)": "+0.28",
    "Correlation with Bitcoin (BTC)": "-0.03",
    "Correlation with Gold (XAU)": "+0.00"
   }
  },
  {
   "id": "trade-plans",
   "title": "DHR Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (40.5) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$213.48",
    "TARGET 2": "$217.63",
    "TARGET 3": "$223.85",
    "STOP LOSS": "$196.63"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+2.21%",
    "Average Feb return": "-2.22%",
    "Average Mar return": "-0.52%",
    "Average Apr return": "+1.58%",
    "Average May return": "+1.03%",
    "Average Jun return": "+2.70%",
    "Average Jul return": "+5.58%",
    "Average Aug return": "+1.88%",
    "Average Sep return": "-0.60%",
    "Average Oct return": "-2.04%",
    "Average Nov return": "+4.65%",
    "Average Dec return": "-0.06%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.84%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in DHR in September 2016 would be worth about $30,842 today, compared with about $35,497 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in DHR today could grow to about $24,865 by 2036 in the base case, with a bull case near $71,810 and a bear case around $8,610. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "DHR Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $301 for DHR by 2030 in the base case, from $209 today (1.4x over 4 years). The downside path ends near $154. These are outcomes of a Monte Carlo simulation run on DHR's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using DHR's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "DHR simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$164",
        "$229",
        "$321"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$156",
        "$251",
        "$404"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$154",
        "$275",
        "$492"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$154",
        "$301",
        "$589"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$156",
        "$330",
        "$699"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$159",
        "$362",
        "$822"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$163",
        "$396",
        "$962"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$168",
        "$434",
        "$1,120"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$174",
        "$475",
        "$1,300"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$180",
        "$521",
        "$1,503"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "CI The Cigna Group NYSE $288.98 -0.37%",
     "url": "https://clearank.com/stock/cigna-group-ci/"
    },
    {
     "text": "A Agilent Technologies, Inc. NYSE $150.27 +2.36%",
     "url": "https://clearank.com/stock/agilent-technologies-a/"
    },
    {
     "text": "NVO Novo Nordisk A/S Sponsored NYSE $42.53 -2.12%",
     "url": "https://clearank.com/stock/novo-nordisk-nvo/"
    },
    {
     "text": "ILMN Illumina Inc. NASDAQ $222.36 +6.80%",
     "url": "https://clearank.com/stock/ilmn-stock-analysis/"
    },
    {
     "text": "CRNX Crinetics Pharmaceuticals, Inc. NASDAQ $84.95 +0.00%",
     "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
    },
    {
     "text": "TLRY Tilray Brands Inc. NASDAQ $3.99 -3.62%",
     "url": "https://clearank.com/stock/tilray-brands-tlry/"
    },
    {
     "text": "AMGN Amgen Inc. NASDAQ $375.65 -1.53%",
     "url": "https://clearank.com/stock/amgen-amgn/"
    },
    {
     "text": "PFE Pfizer Inc. NYSE $27.55 -0.61%",
     "url": "https://clearank.com/stock/pfizer-pfe/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "IONQ vs QBTS Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/ionq-vs-qbts/"
    },
    {
     "text": "CLS vs SMCI Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/cls-vs-smci/"
    },
    {
     "text": "MCD vs SBUX Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/mcd-vs-sbux/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "DHR Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$507.5M",
    "Insiders": "25",
    "Avg Transaction": "$39.0M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in DHR",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Nov 4, 2021",
       "cells": [
        "RALES MITCHELL P Officer and Director",
        "Sell",
        "1.2M",
        "$377.9M"
       ]
      },
      {
       "label": "May 12, 2025",
       "cells": [
        "RALES STEVEN M Chairman of the Board",
        "Sell",
        "1.3M",
        "$245.9M"
       ]
      },
      {
       "label": "Oct 31, 2025",
       "cells": [
        "RALES MITCHELL P Officer and Director",
        "Sell",
        "600.0K",
        "$129.6M"
       ]
      },
      {
       "label": "Nov 12, 2025",
       "cells": [
        "RALES MITCHELL P Officer and Director",
        "Sell",
        "437.0K",
        "$95.6M"
       ]
      },
      {
       "label": "Jul 24, 2020",
       "cells": [
        "JOYCE THOMAS PATRICK JR Chief Executive Officer",
        "Sell",
        "181.4K",
        "$35.2M"
       ]
      },
      {
       "label": "May 24, 2019",
       "cells": [
        "DANIEL WILLIAM K II Officer",
        "Sell",
        "164.2K",
        "$21.7M"
       ]
      },
      {
       "label": "Jan 31, 2020",
       "cells": [
        "JOYCE THOMAS PATRICK JR Chief Executive Officer",
        "Sell",
        "132.5K",
        "$21.5M"
       ]
      },
      {
       "label": "Jul 27, 2020",
       "cells": [
        "COMAS DANIEL L Officer",
        "Sell",
        "100.0K",
        "$19.5M"
       ]
      },
      {
       "label": "Aug 31, 2020",
       "cells": [
        "LALOR ANGELA S Officer",
        "Sell",
        "77.9K",
        "$16.0M"
       ]
      },
      {
       "label": "Feb 3, 2020",
       "cells": [
        "COMAS DANIEL L Officer",
        "Sell",
        "82.5K",
        "$13.3M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Danaher+Corp.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is Danaher Corp. stock a buy right now?",
   "answer": "Danaher Corp. (DHR) is currently rated as 'Hold' by our consensus, with a score of 59. While Wall Street analysts largely recommend 'Buy' with a median price target of $230, significant insider selling and below-sector-average revenue growth present considerable risks that temper a strong buy recommendation."
  },
  {
   "question": "What is Danaher Corp.'s stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Danaher Corp.'s (DHR) stock price forecast for 2030 shows a base case of $301.39, a downside projection of $154.10, and an upside projection of $589.44. These figures represent statistical outcomes and are not definitive price targets."
  },
  {
   "question": "How does Danaher Corp. compare to its sector averages?",
   "answer": "Danaher Corp. (DHR) shows a higher Return on Equity (7.61%) and Profit Margin (15.95%) compared to sector medians (ROE 6.9%, PS 3.7). However, its revenue growth (5.5%) trails the sector median (8.1%), and its P/S ratio (5.69) is above the sector average."
  },
  {
   "question": "What are the main concerns for Danaher Corp. investors?",
   "answer": "The primary concern for Danaher Corp. (DHR) investors is the substantial insider selling, totaling over $507 million, which raises questions about management's confidence. Additionally, the company's revenue growth is lagging behind its healthcare sector peers."
  },
  {
   "question": "What is the Wall Street consensus on Danaher Corp. stock?",
   "answer": "Wall Street analysts collectively hold a 'Buy' rating on Danaher Corp. (DHR), with 5 analysts rating it 'Strong Buy' and 17 rating it 'Buy'. The consensus score is 76 out of 100, and the median price target is $230, suggesting a potential upside of 9.9% from the current price."
  },
  {
   "question": "What has been Danaher Corp.'s recent earnings performance?",
   "answer": "Danaher Corp. (DHR) has experienced mixed earnings results recently. While it beat estimates for the quarter ending March 2026 and one quarter ending June 2026, another quarter ending June 2026 showed a negative EPS surprise. This inconsistency warrants close monitoring of future earnings reports."
  },
  {
   "question": "Are there any significant catalysts expected for Danaher Corp.?",
   "answer": "While no specific upcoming catalysts are detailed, Danaher Corp.'s (DHR) performance will likely be influenced by its ability to execute on its growth strategies and manage operational efficiencies. Investors should monitor company announcements for potential new contracts or strategic initiatives within the diagnostics and research space."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "CI",
    "name": "The Cigna Group NYSE",
    "price": "$288.98",
    "change": "-0.37%",
    "url": "https://clearank.com/stock/cigna-group-ci/"
   },
   {
    "ticker": "A",
    "name": "Agilent Technologies, Inc. NYSE",
    "price": "$150.27",
    "change": "+2.36%",
    "url": "https://clearank.com/stock/agilent-technologies-a/"
   },
   {
    "ticker": "NVO",
    "name": "Novo Nordisk A/S Sponsored NYSE",
    "price": "$42.53",
    "change": "-2.12%",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   },
   {
    "ticker": "ILMN",
    "name": "Illumina Inc. NASDAQ",
    "price": "$222.36",
    "change": "+6.80%",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "CRNX",
    "name": "Crinetics Pharmaceuticals, Inc. NASDAQ",
    "price": "$84.95",
    "change": "+0.00%",
    "url": "https://clearank.com/stock/crinetics-pharmaceuticals-crnx/"
   },
   {
    "ticker": "TLRY",
    "name": "Tilray Brands Inc. NASDAQ",
    "price": "$3.99",
    "change": "-3.62%",
    "url": "https://clearank.com/stock/tilray-brands-tlry/"
   },
   {
    "ticker": "AMGN",
    "name": "Amgen Inc. NASDAQ",
    "price": "$375.65",
    "change": "-1.53%",
    "url": "https://clearank.com/stock/amgen-amgn/"
   },
   {
    "ticker": "PFE",
    "name": "Pfizer Inc. NYSE",
    "price": "$27.55",
    "change": "-0.61%",
    "url": "https://clearank.com/stock/pfizer-pfe/"
   }
  ],
  "comparisons": [
   {
    "ticker": "IONQ vs QBTS Comparison",
    "name": "",
    "url": "https://clearank.com/compare/ionq-vs-qbts/"
   },
   {
    "ticker": "CLS vs SMCI Comparison",
    "name": "",
    "url": "https://clearank.com/compare/cls-vs-smci/"
   },
   {
    "ticker": "MCD vs SBUX Comparison",
    "name": "",
    "url": "https://clearank.com/compare/mcd-vs-sbux/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "IAUM",
    "text": "iShares Gold Trust Micro",
    "url": "https://clearank.com/etf/iaum-etf-analysis/"
   },
   {
    "ticker": "SLVR",
    "text": "Sprott Silver Miners & Physical Silver ETF",
    "url": "https://clearank.com/etf/slvr-etf-analysis/"
   },
   {
    "ticker": "NTES",
    "text": "NetEase, Inc.",
    "url": "https://clearank.com/stock/ntes-stock-analysis/"
   },
   {
    "ticker": "PCAR",
    "text": "PACCAR Inc.",
    "url": "https://clearank.com/stock/pcar-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "CRV/USD",
    "text": "↓ 11.53%",
    "url": "https://clearank.com/crypto/crv-usd-crypto-analysis/"
   },
   {
    "ticker": "CRCL",
    "text": "↓ 11.41%",
    "url": "https://clearank.com/stock/circle-internet-group-crcl/"
   },
   {
    "ticker": "TEM",
    "text": "↑ 10.67%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   },
   {
    "ticker": "COIN",
    "text": "↓ 10.10%",
    "url": "https://clearank.com/stock/coinbase-coin/"
   },
   {
    "ticker": "AXON",
    "text": "↓ 9.98%",
    "url": "https://clearank.com/stock/axon-enterprise-axon/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "A",
    "text": "Agilent Technologies Inc.",
    "url": "https://clearank.com/stock/agilent-technologies-a/"
   },
   {
    "ticker": "IDXX",
    "text": "IDEXX",
    "url": "https://clearank.com/stock/idxx-stock-analysis/"
   },
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "IQV",
    "text": "IQVIA Holdings Inc.",
    "url": "https://clearank.com/stock/iqvia-iqv/"
   },
   {
    "ticker": "NTRA",
    "text": "Natera, Inc.",
    "url": "https://clearank.com/stock/natera-ntra/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/dhr-stock-analysis.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/dhr-stock-analysis.png",
     "width": "1280",
     "height": "720",
     "caption": "Danaher (DHR) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/dhr-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/dhr-stock-analysis/",
        "name": "Danaher (DHR) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/dhr-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/dhr-stock-analysis/",
     "name": "Danaher (DHR) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-19T09:37:05+00:00",
     "dateModified": "2026-09-16T04:45:53+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/dhr-stock-analysis.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/dhr-stock-analysis/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/dhr-stock-analysis/#richSnippet",
     "headline": "Danaher (DHR) Stock Forecast & Price Target (2026)",
     "name": "Danaher (DHR) Stock Forecast & Price Target (2026)",
     "description": "Danaher Corp. (DHR) stock: Healthcare, Diagnostics & Research. $147.2B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-19T09:37:05+00:00",
     "dateModified": "2026-09-16T04:45:53+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Danaher Corp.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "DHR"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Danaher Corp. is a global science and technology company focused on biotechnology, life sciences, and diagnostics. The company develops and supplies mission-critical tools, consumables, instruments, software, and services used in research, bioprocessing, clinical testing, and laboratory workflows. I",
      "tickerSymbol": "DHR",
      "sameAs": "https://www.danaher.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/dhr-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/dhr-stock-analysis.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/dhr-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is Danaher Corp. stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Danaher Corp. (DHR) is currently rated as 'Hold' by our consensus, with a score of 59. While Wall Street analysts largely recommend 'Buy' with a median price target of $230, significant insider selling and below-sector-average revenue growth present considerable risks that temper a strong buy recommendation."
     }
    },
    {
     "@type": "Question",
     "name": "What is Danaher Corp.'s stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Danaher Corp.'s (DHR) stock price forecast for 2030 shows a base case of $301.39, a downside projection of $154.10, and an upside projection of $589.44. These figures represent statistical outcomes and are not definitive price targets."
     }
    },
    {
     "@type": "Question",
     "name": "How does Danaher Corp. compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Danaher Corp. (DHR) shows a higher Return on Equity (7.61%) and Profit Margin (15.95%) compared to sector medians (ROE 6.9%, PS 3.7). However, its revenue growth (5.5%) trails the sector median (8.1%), and its P/S ratio (5.69) is above the sector average."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main concerns for Danaher Corp. investors?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary concern for Danaher Corp. (DHR) investors is the substantial insider selling, totaling over $507 million, which raises questions about management's confidence. Additionally, the company's revenue growth is lagging behind its healthcare sector peers."
     }
    },
    {
     "@type": "Question",
     "name": "What is the Wall Street consensus on Danaher Corp. stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Wall Street analysts collectively hold a 'Buy' rating on Danaher Corp. (DHR), with 5 analysts rating it 'Strong Buy' and 17 rating it 'Buy'. The consensus score is 76 out of 100, and the median price target is $230, suggesting a potential upside of 9.9% from the current price."
     }
    },
    {
     "@type": "Question",
     "name": "What has been Danaher Corp.'s recent earnings performance?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Danaher Corp. (DHR) has experienced mixed earnings results recently. While it beat estimates for the quarter ending March 2026 and one quarter ending June 2026, another quarter ending June 2026 showed a negative EPS surprise. This inconsistency warrants close monitoring of future earnings reports."
     }
    },
    {
     "@type": "Question",
     "name": "Are there any significant catalysts expected for Danaher Corp.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "While no specific upcoming catalysts are detailed, Danaher Corp.'s (DHR) performance will likely be influenced by its ability to execute on its growth strategies and manage operational efficiencies. Investors should monitor company announcements for potential new contracts or strategic initiatives within the diagnostics and research space."
     }
    }
   ]
  }
 ]
}